Market research
ONCS OncoSec Medical Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 110
- Dividend yield
- 0.0%
- Beta
- 2.0
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology & Medical Research
- ISIN
- US68234L3069
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 110
- Dividend yield
- 0.0%
- Beta
- 2.0
About
About OncoSec Medical Inc
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ONCS discussion.
5 years, 4 months ago
OncoSec Medical Incorporated is currently in a long term downtrend where the price is trading 32.3% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
OncoSec Medical Incorporated's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 21.5% to $-11M since the same quarter in the previous year.
Finally, its free cash flow fell by 45.8% to $-11M since the same quarter in the previous year.
Based on the above factors, OncoSec Medical Incorporated gets an overall score of 2/5.